Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 45 |
| Active Pipeline (Recruiting Now) | 23 (16) |
| Completed vs Stopped Early | 7 / 0 (0.0%) |
| Median Closed Actual Enrollment | 60 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 16 |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi | 14 |
| Henan Provincial People's Hospital | Zhengzhou | 14 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07378527 | Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria | Phase II/III | RECRUITING |
| NCT06842199 | Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis | Phase III | RECRUITING |
| NCT07440537 | Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study | Phase II | RECRUITING |
| NCT07047612 | ICP-332 in Subjects With Non-segmental Vitiligo | Phase II/III | RECRUITING |
| NCT06775860 | ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Beijing InnoCare Pharma Tech Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.